Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Glioblastoma 4Brain Neoplasms 4Astrocytoma 4Oligodendroglioma 3Gliosarcoma 3Glioma 3Central Nervous System Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Medulloblastoma 1Head and Neck Neoplasms 1Familial ependymoma 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 150Radiotherapy 121Cetuximab 96Docetaxel 60Fluorouracil 56Paclitaxel 45Radiotherapy, Intensity-Modulated 41Carboplatin 40pembrolizumab 34Surveys and Questionnaires 22Erlotinib Hydrochloride 19Nivolumab 18Immunohistochemistry 16Gefitinib 16Drug Therapy 16Gemcitabine 14Pemetrexed 13Gene Expression Profiling 13durvalumab 12Chemotherapy, Adjuvant 12Radiation 11Filgrastim 11Bevacizumab 11Surgical Procedures, Operative 10Polymerase Chain Reaction 10Amifostine 10Celecoxib 9Capecitabine 9Standard of Care 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Head and Neck Neoplasms × Genetic Therapy × Clear all
NCT00006033 2013-05-30

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡